Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US.Albery Bourla said there ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

CEO Albert Bourla is waiting for the US government to decide whether to place a 25% tariff on pharmaceutical imports.

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Pfizer CEO Albert Bourla gave an optimistic read on Tuesday when asked how he thought the trade levies might be implemented.

Pfizer CEO says tariffs are discouraging the company from investing in the US. Pfizer's full-year guidance does not factor in ...

Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Pfizer’s chief executive, Albert Bourla, told investors that the uncertainty surrounding President Donald Trump’s proposed tariffs on imported medicines is ...